LOS ANGELES--(BUSINESS WIRE)--May 18, 2006--Abraxis BioScience, Inc. (NASDAQ:ABBI - News), an integrated, global biopharmaceutical company, today announced it has increased its research facilities with the addition of a 50,750 square foot facility located in Marina del Rey, California. This facility contains 20,000 square feet of cGMP-compliant production space designed for the manufacture of clinical trial materials for cell-based biotechnology products including whole cell vaccines and stem cell therapies. The facility, which was formerly owned by CancerVax, Inc., will now be used by Abraxis to expand the company’s research and process development capabilities, including biosimilars, as well as house the company’s regulatory affairs and medical writing staff.
